Akebia Therapeutics, Inc.

AKBA · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$540$247$6,112-$22,804
Dep. & Amort.$318$316$314$13,543
Deferred Tax$0$0$0$0
Stock-Based Comp.$3,221$0$2,187$0
Change in WC$19,227$5,100-$29,726-$3,231
Other Non-Cash$4,799$16,682$7,526$8,026
Operating Cash Flow$28,105$22,345-$13,587-$4,466
Investing Activities
PP&E Inv.-$77-$126-$18-$2
Net Acquisitions$0$0$172$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$77-$126$154-$2
Financing Activities
Debt Repay.$0$0$9,538-$1,271
Stock Issued$152$1,720$64,985$22,324
Stock Repurch.$0$0-$63$0
Dividends Paid$0$0$0$0
Other Fin. Act.$961$0$482$1,272
Financing Cash Flow$1,113$1,720$74,942$22,325
Forex Effect$0-$5$0-$6
Net Chg. in Cash$29,141$23,934$61,509$17,851
Supplemental Information
Beg. Cash$138,998$113,374$53,550$34,019
End Cash$168,139$137,308$115,059$51,870
Free Cash Flow$28,028$22,219-$13,605-$4,468